Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 14/20 | 0.65 |
| ▸ | AKT1 | P31749 | 5/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.65 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247478 | 0.81 | AKT2 (0.59) | AKT2AKT1ROCK2CYP2C9KIT | |
| SCHEMBL2779642 | 0.79 | AKT2 (0.74) | AKT2AKT1ROCK2CYP2C9KCNH2 | |
| SCHEMBL19753047 | 0.79 | AKT2 (0.71) | AKT2AKT1ROCK2CYP2C9KCNH2 | |
| SCHEMBL19228430 | 0.78 | RPS6KB1 (0.69) | AKT2AKT1ROCK2CYP2C9KCNH2 | |
| SCHEMBL1001031 | 0.78 | AKT2 (1.00) | AKT2AKT1ROCK2CYP2C9KCNH2 | |
| SCHEMBL2780589 | 0.78 | AKT2 (1.00) | AKT2AKT1ROCK2CYP2C9KCNH2 | |
| SCHEMBL13885868 | 0.78 | AKT2 (0.74) | AKT2AKT1ROCK2CYP2C9KCNH2 | |
| SCHEMBL19228241 | 0.77 | RPS6KB1 (0.70) | AKT2AKT1ROCK2CYP2C9KCNH2 | |
| SCHEMBL13885616 | 0.76 | AKT2 (0.68) | AKT2AKT1ROCK2CYP2C9KCNH2 | |
| SCHEMBL2782629 | 0.76 | AKT2 (0.68) | AKT2AKT1ROCK2CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| EP-2013206-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, CDK1 | AKT2 43/4885AKT1 72/4885ROCK2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.